alpha-tocopherol acetate
fatro s.p.a. - dl-alpha-tocopherol acetate 50% - unknown - dl-alpha-tocopherol acetate 50% vitamin-e active 0.0 - active constituent
blackmores evening primrose oil
blackmores ltd - evening primrose oil, quantity: 1 g (equivalent: gamma-linolenic acid, qty 100 mg) - capsule, soft - excipient ingredients: gelatin; glycerol; lecithin; soya oil; d-alpha-tocopherol; medium chain triglycerides; purified water
anti age skin- alpha-tocopherol - ascophyllum nodosum - botryoglossum platycarpum - fucus serratus - fucus vesiculosus - isoleuc
guna spa - alpha-tocopherol (unii: h4n855pnz1) (alpha-tocopherol - unii:h4n855pnz1), laminaria digitata (unii: 15e7c67ee8) (laminaria digitata - unii:15e7c67ee8), botryoglossum platycarpum (unii: pta4328m4z) (botryoglossum platycarpum - unii:pta4328m4z), fucus serratus (unii: v8k40wnw5b) (fucus serratus - unii:v8k40wnw5b), sus scrofa capillary tissue (unii: 253a0356pn) (sus scrofa capillary tissue - unii:253a0356pn), ubidecarenone (unii: ej27x76m46) (ubidecarenone - unii:ej27x76m46), sus scrofa collagen (unii: i - alpha-tocopherol 4 [hp_c] in 4 g - alpha tocopherol 4c antioxidant brown algae, laminaria 4c detoxification and drainage brown algae, platycarpus 4c detoxification and drainage brown algae, serratus 4c detoxification and drainage capillary tissue 4c blood flow support coenzyme q-10 4c antioxidant collagen 4c eutrophic action fucus vesiculosus 4c detoxification isoleucine 4c dermis protein metabolic support knotted wrack 4c skin tone support leucine 4c dermis protein metabolic support placenta totalis 4c vascular stimulation retinol 4c antioxidant sea lettuce 4c skin tone selenium metallicum 4c cell metabolic support skin tissue 4c eutrophic supp
kangpai maxepa/evening primrose oil capsule bulk
kangpai international pty ltd - evening primrose oil, quantity: 500 mg (equivalent: gamma-linolenic acid, qty 40 mg); natural fish oil, quantity: 500 mg (equivalent: eicosapentaenoic acid, qty 90 mg; equivalent: docosahexaenoic acid, qty 60 mg) - capsule, soft - excipient ingredients: gelatin; glycerol; purified water; d-alpha-tocopheryl acetate - for use as a dietary supplement providing essential fatty acids, incl.omega-3 marine triglycerides and gamma-linolenic acid
prolastin c liquid alpha-1-proteinase inhibitor (human) 1000 mg solution for injection for intravenous infusion vial
grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: monobasic sodium phosphate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1-antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.
prolastin c liquid alpha-1-proteinase inhibitor (human) 4000 mg solution for injection for intravenous infusion vial
grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.
prolastin c liquid alpha-1-proteinase inhibitor (human) 500 mg solution for injection for intravenous infusion vial
grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.
alpha1-proteinase inhibitor (human) powder for solution
grifols therapeutics llc - alpha1-proteinase inhibitor (human) - powder for solution - 500mg - alpha1-proteinase inhibitor (human) 500mg - enzymes
alpha1-proteinase inhibitor (human) powder for solution
grifols therapeutics llc - alpha1-proteinase inhibitor (human) - powder for solution - 1g - alpha1-proteinase inhibitor (human) 1g - enzymes
zemaira- alpha-1-proteinase inhibitor human kit zemaira- .alpha.1-proteinase inhibitor human kit
csl behring llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - zemaira is an alpha1 -proteinase inhibitor (a1 -pi) indicated for chronic augmentation and maintenance therapy in adults with a1 -pi deficiency and clinical evidence of emphysema. zemaira increases antigenic and functional (anti-neutrophil elastase capacity [anec]) serum levels and lung epithelial lining fluid (elf) levels of a1 -pi. clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with zemaira are not available. the effect of augmentation therapy with zemaira or any a1 -pi product on pulmonary exacerbations and on the progression of emphysema in a1 -pi deficiency has not been demonstrated in randomized, controlled clinical studies. zemaira is not indicated as therapy for lung disease patients in whom severe a1 -pi deficiency has not been established. - zemaira is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to zemaira or a1 -pi protein. - zemaira is contraindicated in immunoglobulin a (iga)-deficient patients with antibodies against iga, due to the risk of severe hypersensitivity [see warnings and precautions (5.2)] . risk summary no animal reproduction studies have been conducted with zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. since alpha1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that zemaira will cause harm to the fetus when given at recommended doses. however, zemaira should be given with caution to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the excretion of zemaira in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zemaira and any potential adverse effects on the breastfed infant from zemaira or from the underlying maternal condition. safety and effectiveness in the pediatric population have not been established. the safety and efficacy of zemaira in the geriatric population have not been established due to an insufficient number of subjects.